Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 3, 2009, Pages 311-317

  Hotta, Katsuyuki ^a   Fujiwara, Yoshiro ^a   Matsuo, Keitaro ^b   Kiura, Katsuyuki ^a   Takigawa, Nagio ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Non small cell lung cancer; Overall survival; Surrogate marker; Time to progression

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; CAUSE OF DEATH; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; LUNG TUMOR; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROBABILITY; REVIEW; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SURVIVAL; TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CAUSE OF DEATH; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROBABILITY; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67049167808     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181989bd2     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311: 899-909.
3. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859. (Pubitemid 41079865)
4. Hotta K, Matsuo K. Long-standing debate on cisplatin- versus carboplatin- based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007;2:96. (Pubitemid 47163939)
5. Hotta K, Fujiwara Y, Matsuo K, et al. Recent improvement in the survival of patients with advanced non-small-cell lung cancer enrolled in phase III trials of first-line systemic chemotherapy. Cancer 2007;109: 939-948. (Pubitemid 46333536)
6. Yamanaka T, Okamoto T, Ichinose Y, Oda S, Maehara Y. Methodological aspects of current problems in target-based anticancer drug development. Int J Clin Oncol 2006;11:167-175. (Pubitemid 44087114)
7. Hotta K, Ueoka H. New cytotoxic agents: a review of the literature. Crit Rev Oncol Hematol 2005;55:45-65. (Pubitemid 40779474)
8. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-938.
9. Begg CB, Leung DHY. On the use of surrogate end points in randomized trials. J R Stat Soc (Ser A) 2000;163:15-24.
10. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562-4568.
11. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients in 18 randomized trials. J Clin Oncol 2005;23:8664-8670.
12. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 2005;93:1215-1221. (Pubitemid 41679406)
13. Johnson KR, Ringland C, Stokes BJ, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006;7:741-746. (Pubitemid 44283658)
14. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
15. Chu TM, Weir B, Wolfinger R. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 2002;176: 35-51. (Pubitemid 34242098)
16. Hotta K, Fujiwara Y, Kiura K, et al. Relationship between response rate and survival in over 50,000 patients of advanced non-small-cell lung cancer treated with systemic chemotherapy. J Thorac Oncol 2007;2: 402-407. (Pubitemid 47181694)
17. Buyse M. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2838 patients randomized in 7 trials. Proc Am Soc Clin Oncol 2008;abstract #8019.
18. Tripathy D. Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials. Oncologist 2007;12:375-389. (Pubitemid 46698715)
19. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
20. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancerpreviously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
21. Douillard JY. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). J Thorac Oncol 2007;2:S305 (12th World Conference on Lung Cancer #PRS-02).
22. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
23. Hotta K, Fujiwara Y, Matsuo K. Author reply to recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007;110:2594. (Pubitemid 350174948)
24. Manegold C, von Pawel J, Zatloukal P, et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc Am Soc Clin Oncol 2007;LBA7514.
25. http://www.clinicaltrials.gov/ct/show/NCT00322452. Accessed on September 13, 2008.
26. Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC)-comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group Trials before and after 1990. Cancer 2000;106:2208 -2217, 200.
27. United States Food and Drug Administration: Guidance for industry clinical trial endpoints for the approval of cancer drugs and biologics. http://www.fda.gov/cder/guidance/7478fnl.htm. Accessed on September 13, 2008.
28. Lara PN Jr, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26:463-467. (Pubitemid 351171700)
29. Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol 2007;2:735-740. (Pubitemid 47357528)
30. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-440. (Pubitemid 19105891)
31. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.